New insider activity at Amicus ( (FOLD) ) has taken place on December 17, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bradley Campbell, President and CEO of Amicus, has made a significant transaction by selling 77,926 shares of Amicus stock. This sale was valued at an impressive $845,497, showcasing a notable move by the company’s leadership.
Recent Updates on FOLD stock
Recent developments for Amicus Therapeutics have highlighted notable market optimism. Analysts have initiated or raised price targets based on the company’s promising sales potential for its rare disease therapies, particularly Galafold and PomOp, which are expected to collectively achieve over $1 billion in sales by 2028. The upward revisions to price targets reflect strong quarterly earnings growth and the company’s robust financial performance. These positive indicators underscore confidence in Amicus’s growth prospects and ability to execute on its commercial strategies.
Spark’s Take on FOLD Stock
According to Spark, TipRanks’ AI Analyst, FOLD is a Neutral.
Amicus Therapeutics shows strong technical momentum and positive earnings call sentiment, indicating potential for growth. However, financial performance challenges and valuation concerns weigh on the overall score.
To see Spark’s full report on FOLD stock, click here.
More about Amicus
YTD Price Performance: 16.97%
Average Trading Volume: 5,480,293
Technical Sentiment Signal: Buy
Current Market Cap: $3.36B